Ullman Cited in Article on FDA’s Takedown of NMN

November 15, 2022 | Compliance Investigations & White Collar | Health Services

Marc Ullman was cited in the NutraIngredientsUSA article, “FDA’s takedown of NMN raises fairness transparency concerns.”

The FDA has disallowed the anti-aging ingredient, NMN, and this has raised questions of fairness and transparency.

Ullman said the current FDA interpretation sets up a situation in which a pharma company could file an IND, let the issue lie fallow, and then reinvigorate its drug development after a supplemental company has developed new applications for the same substance.

“This interpretation will have a chilling effect on the development of new products to support public health,” stated Ullman.

Read the full article here.

Share this article:

Related News

Get legal updates and news delivered to your inbox